Table 2.
References | Type of study | Type of host | Age of the host (weeks) | Way of infectiona | Stage parasite | Strainb | Number of parasites | Days post-infection | Analysis techniquec | Hormonesd | Groupe | N | Resultsf | p | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Kittas and Henry, 1979 | In vivo | Guinea-pigs | NS | SC | Cysts | Bk | 50 | 42 | Number of Toixoplasma cysts ± SD | ||||||
HIS | 17β-estradiol (E2) | Control F: | 8 | 88.75 ± 21.60 | ||||||||||||
Control M: | 8 | 82.50 ± 21.1* | <0.001 | |||||||||||||
Gdt F: | 8 | 63.00 ± 16.5 | ↓ | |||||||||||||
Gdt M: | 8 | 65.25 ± 10.8 | ↓ | |||||||||||||
Gdt + Hex F: | 8 | 200.25 ± 16.00 | ↑ | |||||||||||||
Gdt + Hex M: | 8 | 184.00 ± 36.80 | ↑ | |||||||||||||
2 | Kittas and Henry, 1980 | In vivo | Mice | 11 | SC | Cysts | Bk | 30 | 42 | Number of Toxoplasma cysts ± SD | ||||||
HIS | 17β-estradiol | Control F: | 8 | 222 ± 42 | ||||||||||||
(E2) | Control M: | 8 | 220 ± 23 | |||||||||||||
Gdt F: | 8 | 189 ± 22* | ↓ | <0.001 | ||||||||||||
Gdt M: | 8 | 178 ± 24* | ↓ | <0.001 | ||||||||||||
Gdt + Hex F: | 8 | 598 ± 64* | ↑ | <0.001 | ||||||||||||
Gdt + Hex M: | 8 | 599 ± 45* | ↑ | <0.001 | ||||||||||||
3 | Pung and Luster, 1986 | In vivo | Mice (B6C3F1) | 8–10 | SC | Cysts | T45 | 30 | 35 | Number of Toxoplasma cysts ± SD | ||||||
RIA | Control | 6 | 982 ± 194 | |||||||||||||
DES | 6 | 2244 ± 66* | ↑ | <0.05 | ||||||||||||
17β-estradiol | 6 | 1934 ± 198* | ↑ | <0.05 | ||||||||||||
5α-Dihydrotesti osterone | 6 | 792 ± 164 | ↓ | |||||||||||||
Progesterone | 6 | 1012 ± 172 | ↑ | |||||||||||||
Zeralanol | 6 | 1463 ± 190 | ↑ | |||||||||||||
a-Dienestrol | 6 | 2405 ± 227* | ↑ | <0.05 | ||||||||||||
Corticosterone | 6 | 1954 ± 314* | ↑ | <0.05 | ||||||||||||
Effect of Tamoxifen, number of cysts ± SD | ||||||||||||||||
RIA | 17β-estradiol (E2) | Control | 6 | 1115 ± 112 | ||||||||||||
Tamoxifen | 6 | 975 ± 124 | ↓ | |||||||||||||
17β-estradiol | 6 | 2220 ± 182* | ↑ | <0.05 | ||||||||||||
Tamoxifen + E2 | 6 | 1027 ± 167 | ↓ | |||||||||||||
4 | Fredriksson et al., 1990 | In vivo | Ewes (Scottish blackface) | NS | Oral | Oocysts | RH | 2000 | 90.5 | Progesterone levels (nM/L) | ||||||
RIA | Progesterone (P4) | Control | 3 | 10–20 | ||||||||||||
Infected | 13 | 10 | ↓ | NS | ||||||||||||
Vaccinated | 15 | 10 | ↓ | NS | ||||||||||||
5 | Aiumalamai et al., 1990 | In vivo | Ewes (Swedish Peltsheep) | 52–104 | NS | Oocysts | NS | NS | 90.5 | Progesterone levels (nM/L) | ||||||
RIA | Progesterone (P4) | 7 | Day 5: 6–8 | |||||||||||||
Days 10 a 15: 19- | ↑ | <0.05 | ||||||||||||||
6 | Hulínská et al., 1990 | In vivo | Mice (H VUFB) | 4–5 | IP | Cysts | P78 | 10 | Number of tachyzoites and stozoites | |||||||
5–14 | HIS y MIC | Cortisone | Group 1 | 20 | 10–14 days | ↑ | – | |||||||||
12–47 | Group 2 | 20 | ||||||||||||||
7 | Engeland et al., 1996 | In vivo | Goat (Norwegian) | NS | SC | Bradyzoites | NS | 1250 | 54–73 | Progesterone levels | ||||||
ELISA y SF | Progesterone (P4) | Control | 6 | |||||||||||||
Infected | 5 | |||||||||||||||
8 | Stahl and Kaneda, 1998a | In vivo | Mice (Nya: NYLAR) | NS | IP | Cysts | CS | 8 | 3 and 4 | T4 levels (Mean) | ||||||
RIA | Thyroxine (T4) | Control | 10 | 7.5 | ||||||||||||
Infected | 10 | 3 | ↓ | <0.01 | ||||||||||||
9 | Stahl and Kaneda, 1998a | In vivo | Mice (Nya: NYLAR) | 12 | IP | Cysts | CS | 8 | 4 | Subnormal T4 response to a 1 |ig bolus or TRH (Mean) | ||||||
RIA | Thyroxine (T4) | Control | 8 | 11 | ||||||||||||
Infected | 8 | 3 | ↓ | <0.01 | ||||||||||||
10 | Liesenfeld et al., 2001 | In vivo | Mice (C57BL/6) | 8–10 | Oral | Cysts | ME 49 | 100 | 7 | Number of parasitophorous vacuoles | ||||||
NS | Testosterone | Control | 657 ± 399 | |||||||||||||
Testosteron | 426 ± 282 | ↓ | =0.0141 | |||||||||||||
11 | Kaňková et al., 2011 | In vivo | Mice (BALB/c and C57 Black) | 5–6 | Oral | Cysts | T38 | 10 | 60 | Differences in serum testosterone levels | ||||||
RIA | Testosterone | M. Toxo infected | 12 | Z = −2.32 | ↓ | =0.005 | ||||||||||
M. Controls | 20 | |||||||||||||||
F. Toxo infected | 12 | Z = −2.76 | ↓ | =0.020 | ||||||||||||
F. Controls | 20 | |||||||||||||||
12 | Abdoli et al., 2012 | In vivo | Rats (Wistar) | NS | IP | Tachyzoites | RH | 1 × 107 | Effect of T. gondii infection on Serum Testosterone (ST) | |||||||
10 | ELISA | Testosterone | Uninfected | 5 | 0.6 ± 0.01 | |||||||||||
10 | Infected | 3 | 0.55 ± 0.02* | ↓ | <0.05 | |||||||||||
Effect of T.gondii infection on IntratesticularTestosteron (ITT) | ||||||||||||||||
10 | Uninfected | 5 | 4.07 ± 0.02 | |||||||||||||
10 | Infected | 3 | 3.89 ± 0.05* | ↓ | <0.05 | |||||||||||
13 | Puvanesuaran et al., 2012 | In vivo | Mice (Swiss) | 3 | Oral | Tachyzoites | RH | 1 × 104 | 4 | Number of tachyzoites (Mean) | ||||||
MIC | Prednisolone | Control | 3 | 1.48 × 107 | ||||||||||||
235 mg/kg | 3 | 2.75 × 107 | ↑ | <0.05 | ||||||||||||
470 mg/kg | 3 | 2.92 × 107 | ↑ | <0.05 | ||||||||||||
705 mg/kg | 3 | 3.21 × 107 | ↑ | <0.05 | ||||||||||||
14 | Lim et al., 2013 | In vivo | Rats (Wistar) | 7 | IP | Tachyzoites | PRU | 5 × 106 | 42–56 | % Increase of Testosterona levels | ||||||
ELISA | Testosterone | 54 | 60% | ↑ | =0.057 | |||||||||||
15 | Mitra et al., 2013 | In vivo | Rats | 6.5 | IP | Tachyzoites | PRU | 10 × 106 | 42–56 | Circuling levels of corticosterone | ||||||
ELISA | Corticosterone | 126 | 64% | ↓ | <0.05 |
SC, Subcutaneously; IP, Intraperitoneally; NA, Not Applicable.
Type of strain: BK, Beverley; PRU, Prugniaud; CS, Cornell; RH, ME49, T45, P78, T38.
HIS, Histological; RIA, Radioimmunoassay; MIC, Microscopical; SF, Sabin and Feldman; ELISA, Enzyme-Linked ImmunoSorbent Assay.
E2, 17β-estradiol; P4, Progesterone; T4, Thyroxine; DES, Diethylstilbestrol; ST, Serum Testosterone; ITT, Intra testicular testosterone; TRH, Thyrotropin-Releasing Hormone.
M, Male; F, Female; Gdt, Gonadectomy; Hex, Hexoestrol.
↑, Increased infection; ↓, Decrement infection; ↑, Increased hormone; ↓, Decrement hormone;
and bold, Statistically Significant. NS, Not specified; SD, Standard deviation.